Medesis Pharma S.A. (ALMDP.PA)
EUR 0.34
(-2.86%)
EUR 0.34
(-2.86%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.95 Million EUR | -43.3% |
| 2022 | -2.76 Million EUR | -4.33% |
| 2021 | -2.64 Million EUR | -212.66% |
| 2020 | -847.08 Thousand EUR | 21.49% |
| 2019 | -1.07 Million EUR | -5.58% |
| 2018 | -1.02 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | -1.17 Million EUR | 0.0% |
| 2023 Q2 | -808.03 Thousand EUR | 0.0% |
| 2023 Q1 | -808.03 Thousand EUR | -37.6% |
| 2023 Q3 | -1.17 Million EUR | -45.01% |
| 2023 FY | -3.95 Million EUR | -43.3% |
| 2022 Q1 | -787.23 Thousand EUR | -1.49% |
| 2022 Q4 | -587.22 Thousand EUR | 0.0% |
| 2022 Q3 | -587.22 Thousand EUR | 25.41% |
| 2022 Q2 | -787.23 Thousand EUR | 0.0% |
| 2022 FY | -2.76 Million EUR | -4.33% |
| 2021 FY | -2.64 Million EUR | -212.66% |
| 2021 Q4 | -775.67 Thousand EUR | 0.0% |
| 2021 Q3 | -775.67 Thousand EUR | -41.64% |
| 2021 Q2 | -547.62 Thousand EUR | 0.0% |
| 2021 Q1 | -547.62 Thousand EUR | -153.64% |
| 2020 FY | -847.08 Thousand EUR | 21.49% |
| 2020 Q4 | -215.9 Thousand EUR | 0.0% |
| 2020 Q3 | -215.9 Thousand EUR | -20.18% |
| 2020 Q1 | -179.64 Thousand EUR | 0.0% |
| 2020 Q2 | -179.64 Thousand EUR | 0.0% |
| 2019 FY | -1.07 Million EUR | -5.58% |
| 2018 FY | -1.02 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -12.549% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 97.32% |
| Adocia SA | -21.16 Million EUR | 81.29% |
| Aelis Farma SA | -5.07 Million EUR | 22.027% |
| Biophytis S.A. | -17.02 Million EUR | 76.744% |
| Advicenne S.A. | -7.03 Million EUR | 43.685% |
| genOway Société anonyme | 1.56 Million EUR | 352.587% |
| IntegraGen SA | -171.39 Thousand EUR | -2210.102% |
| Neovacs S.A. | -8.74 Million EUR | 54.715% |
| NFL Biosciences SA | -3.74 Million EUR | -5.714% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 5101.315% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -24.868% |
| Sensorion SA | -22.06 Million EUR | 82.054% |
| Theranexus Société Anonyme | -6.82 Million EUR | 42.011% |
| TME Pharma N.V. | -6.73 Million EUR | 41.219% |
| Valbiotis SA | -7.36 Million EUR | 46.261% |
| TheraVet SA | -1.57 Million EUR | -152.083% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 80.537% |
| argenx SE | -272.91 Million EUR | 98.549% |
| BioSenic S.A. | -28.77 Million EUR | 86.241% |
| Celyad Oncology SA | -8.44 Million EUR | 53.131% |
| DBV Technologies S.A. | -67.26 Million EUR | 94.114% |
| Galapagos NV | 211.69 Million EUR | 101.87% |
| Genfit S.A. | -28.89 Million EUR | 86.296% |
| GeNeuro SA | -14.75 Million EUR | 73.169% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 74.256% |
| Innate Pharma S.A. | -7.57 Million EUR | 47.695% |
| Inventiva S.A. | -110.42 Million EUR | 96.414% |
| MaaT Pharma SA | -19.71 Million EUR | 79.918% |
| MedinCell S.A. | -25.03 Million EUR | 84.186% |
| Nanobiotix S.A. | -39.7 Million EUR | 90.026% |
| Onward Medical N.V. | -36.18 Million EUR | 89.056% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -18.09% |
| OSE Immunotherapeutics SA | -23 Million EUR | 82.787% |
| Oxurion NV | -18.96 Million EUR | 79.127% |
| Pharming Group N.V. | -9.75 Million EUR | 59.417% |
| Poxel S.A. | -35.09 Million EUR | 88.716% |
| GenSight Biologics S.A. | -26.22 Million EUR | 84.899% |
| Transgene SA | -22.32 Million EUR | 82.267% |
| Financière de Tubize SA | 88.15 Million EUR | 104.492% |
| UCB SA | 343 Million EUR | 101.154% |
| Valneva SE | -101.42 Million EUR | 96.096% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 86.03% |